Cargando…
Efficacy and risk of cytotoxic chemotherapy in extensive disease-small cell lung cancer patients with interstitial pneumonia
BACKGROUND: Small cell lung cancer (SCLC) is characterized by a high propensity for metastases and a poor prognosis irrespective of high sensitivity for initial chemotherapy. Although interstitial pneumonia (IP) is one of risk factors for lung cancer, efficacy of cytotoxic chemotherapy for patients...
Autores principales: | Shirasawa, Masayuki, Fukui, Tomoya, Kusuhara, Seiichiro, Hiyoshi, Yasuhiro, Nakahara, Yoshiro, Nishinarita, Noriko, Igawa, Satoshi, Naoki, Katsuhiko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6391765/ https://www.ncbi.nlm.nih.gov/pubmed/30808322 http://dx.doi.org/10.1186/s12885-019-5367-0 |
Ejemplares similares
-
Prognostic differences between oligometastatic and polymetastatic extensive disease-small cell lung cancer
por: Shirasawa, Masayuki, et al.
Publicado: (2019) -
Prognostic significance of the 8th edition of the TNM classification for patients with extensive disease small cell lung cancer
por: Shirasawa, Masayuki, et al.
Publicado: (2018) -
Interstitial pneumonia following administration of pegfilgrastim during carboplatin and etoposide chemotherapy for small-cell lung cancer
por: Shirasawa, Masayuki, et al.
Publicado: (2016) -
Real-world evaluation of carboplatin plus a weekly dose of nab-paclitaxel for patients with advanced non-small-cell lung cancer with interstitial lung disease
por: Igawa, Satoshi, et al.
Publicado: (2018) -
Evaluation of osimertinib efficacy according to body surface area and body mass index in patients with non‐small cell lung cancer harboring an EGFR mutation: A prospective observational study
por: Ono, Taihei, et al.
Publicado: (2019)